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Abstract
Background: Asthma is a complex pulmonary inflammatory disease, which is characterized by airway hyperresponsiveness,
variable airflow obstruction and inflammation in the airways. The majority of asthma is allergic asthma, which is a disease
caused by type I hypersensitivity mediated by IgE. Exposures to a number of environmental chemicals are suspected to lead
to asthma, one such pollutant is di-(2-ethylheyl) phthalate (DEHP). DEHP is a manufactured chemical that is commonly
added in plastic products to make them flexible. Epidemiological studies have revealed a positive association between
DEHP exposure and asthma prevalence.
Methodology/Principal Findings: The present study was aimed to determine the underlying role of DEHP exposure in
airway reactivity, especially when combined with allergen exposure. The biomarkers include pulmonary histopathology,
airway hyperresponsiveness (lung function), IgE, IL-4, IFN-c and eosinophils. Healthy balb/c mice were randomly divided
into eight exposure groups (n=8 each): (1) saline control, (2) 30 mg/(kgNd) DEHP, (3) 300 mg/(kgNd) DEHP, (4) 3000 mg/(kgNd)
DEHP, and (5) ovalbumin (OVA)-sensitized group, (6) OVA-combined with 30 mg/(kgNd) DEHP, (7) OVA-combined with
300 mg/(kgNd) DEHP, and (8) OVA-combined with 3000 mg/(kgNd) DEHP. Experimental tests were conducted after 52-day
DEHP exposure and subsequently one week of challenge with aerosolized OVA. The principal findings include: (1) Strong
postive associations exist between OVA-combined DEHP exposure and serum total IgE (T-IgE), as well as histological
findings. These positive associations show a dose-dependent low dose sensitive effect of DEHP. (2) IL-4, eosinophil
recruitment and lung function are also indicators for adjuvant effect of DEHP.
Conclusions/Significance: Our results suggest that except the significant changes of immunological and inflammatory
biomarkers (T-IgE, IL-4, IFN-c and eosinophils), the pulmonary histological (histopathological examination) and physiological
(lung function) data also support that DEHP may promote and aggravate allergic asthma by adjuvant effect.
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Introduction
Numerous studies have suggested that the notable increase in
allergic subjects seen over the last decades is due to environmental
changes occurring throughout the world [1,2]. It has been
suggested that exposure to specific chemical pollutants in indoor
air and dust may be associated with the development of respiratory
problems [3–7]. Among these chemicals, Di-(2-ethylhexyl) phthal-
ate (DEHP), a commonly used plasticizer in soft poly vinyl chloride
(PVC) materials, is attracting more health concern. ATSDR and
EPA have reported on adverse reproductive effects in which the
daily intake range of DEHP for an adult was estimated to be 3–
30 mg/kg/d [8], and the exposure assessment of NTP-CERHR
was up to 30 mg/kg/d [9]. Generally, children are thought to be
more susceptible since they are more likely to be exposed to
DEHP. ATSDR reported that the daily exposure of children to
DEHP by sucking or chewing on toys or other articles was up to
85 mg/kg/day [8]. And the maximum exposure even exceeded
100 mg/kg/day in some cases. In addition, humans can be
exposed to DEHP during certain medical procedures which are
likely to cause higher exposure than the common everyday routes.
The source of oral exposure to DEHP in the medical device
context includes enteral feeding bags, nasogastric tubing, and
denture materials. In this special case, the estimated amount of
DEHP received by highly exposed individuals from enteral
nutrition storage bags is up to around 2 mg/day. However, the
total amount of DEHP medical oral exposure is unclear [10].
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relationship between exposure to phthalates and PVC materials
and the risk of asthma and allergy both in workers of plastic
industry and in children [11–16]. Some of these studies have
suggested a higher risk of respiratory problems among those
exposed in occupational as well as residential environments.
Several animal studies have indicated that co-administration of
phthalates modulate the immune response to antigen although the
biological mechanism remains unsolved. In one study, DEHP was
showed to provoke a significant increase in the production of IgG1
in a mice model with subcutaneous administration of a model
antigen, ovalbumin (OVA) [17]. In similar studies, MEHP, one
metabolite of DEHP, was found to cause an increase in IgE levels
[18,19]. More recent studies were performed in murine models
mimicking human exposure pathways. Larsen et al. used a long-
term inhalation model with DEHP and reported modulating effect
on IgG1 response as well as inflammatory markers [20]. Ourselves
have reported on DEHP promoting inflammatory responses in
DEHP treated OVA-immunized rats [21]. However, in the studies
by Larsen et al [17,18] immunosuppression was also seen after
injection of high doses of MEHP, not DEHP. And Larsen and
Nielsen reported that extended treatment with DEHP desensitized
OVA-induced immune responses [22]. On the other hand, there
are reports on no antibody response including production of IgE
or Th2 cytokines in DEHP exposed mice but in those studies
topical application of phthalates was used [23,24]. Consequently,
the relevance of DEHP exposure on the development of allergic
asthma is still a controversy.
In addition, most of the previous studies were carried out
applying short term exposure regimes and the models did not
exhibit typical human asthma like properties such as airway
hyperresponsiveness (lung function), histopathological examina-
tion for lung inflammation (lung tissue cell infiltration) and airway
remodeling and/or airway mucus. We, therefore, studied in
greater detail the suspected impact of DEHP on airway reactivity
related to allergic asthma by using a modified long-term oral
exposure OVA-sensitized murine model. This study aimed to
address the effect of long-term DEHP exposure on airway
inflammation and allergic response to OVA related to human
asthma, and to establish a representative experimental platform
for further studies on the molecular mechanisms of DEHP-
induced asthma.
Materials and Methods
Ethics Statement
The experimental procedures were approved by the Office of
Scientific Research Management of Central China Normal
University, with the certification on Application for the Use of
Animals dated March 26, 2010 (approval ID: CCNU-SKY-2010-
005). According to the requirements of ethics only 8 mice were
used in each treatment group to minimize the number of
experimental animals and to ensure the validity of statistical
power.
Animals
Balb/c mice (males, 5–6 weeks old and 17–19 g) were
purchased from the Hubei experimental animal center (Wuhan
China) and housed in cages with pinewood sawdust bedding. They
were maintained in a pathogen-free room at temperatures
between 20–25uC and 50–70% humidity. OVA-free food and
tap water were used. The mice were quarantined for at least 7 days
before study initiation.
Exposure and immunization protocol
The first and the second set of mice were sequentially treated
with the same exposure and immunization protocol. Each set of 64
balc/c mice were randomly divided into eight exposure groups: (1)
saline control (saline control), (2) 30 mg/(kgNd) DEHP (DEHP30),
(3) 300 mg/(kgNd) DEHP (DEHP300), (4) 3000 mg/(kgNd) DEHP
(DEHP3000), (5) OVA-sensitized group (OVA only), (6) OVA-
combined with 30 mg/(kgNd) DEHP (OVA+DEHP30), (7) OVA-
combined with 300 mg/(kgNd) DEHP (OVA+DEHP300), and (8)
OVA-combined with 3000 mg/(kgNd) DEHP (OVA+DEHP3000).
The mice were gavaged with DEHP or saline from day 0 to 51
(52 times), and were sensitized with OVA+ Al(OH)3 (20 mg OVA
and 1.75 mg Al(OH)3 in 300 ml saline each time) or saline (300 ml
saline each time) by subcutaneous injection on day 25, 39 and 47.
This was then followed by an aerosol challenge in 1% OVA
(30 min/d) from days 52 to 58 (7 times) using an ultrasonic
nebulizer (Yuyue 402A type I, China). Before administration
DEHP was dissolved in Tween 80 (CAS No. 9005-65-6, analytical
reagent, Sinopharm Chemical Reagent Co, Ltd. China) (DEHP:
Tween 80 is 1:1 in w/w) together with saline, and then add more
saline to the required volume. All of the DEHP dissolved very well.
The detailed protocol outline is shown in Fig. 1.
To prevent adverse effects on measures of lung cytokines/
pulmonary architecture due to influence from the methacholine
used in airway hyper-responsiveness (AHR; see below) assess-
ments, dedicated groups of mice (for each of the above regimens)
were employed. One set of 64 mice was treated for 59 days
according to the above-regimen(s) and then used for AHR tests
and BALF sample collection; a second set of 64 mice was treated
as above and then used directly (i.e., non-lavaged) for cytokine (left
lung) and histopathologic (right lung) analyses.
Measurement of airway responsiveness
For the first set of 64 balb/c mice airway hyperresponsiveness as
an indicator of lung function was tested 24 hours after the final
aerosol exposure using the AniRes 2005 lung function system
(Bestlab, AniRes 2005, version 2.0, China). Animals were
anesthetized by intraperitoneal injection with pentobarbital
sodium (Urchen) at a dose of 95 mg/kg and were then connected
to a computer-controlled small animal ventilator via a tracheal
cannula. The respiratory rate was preset at 95 times per min and
the time ratio of expiration/inspiration was 1.5:1. When the
parameters were stable, an injector needle was inserted into the
jugular vein and methacholine (O-Acetyl-b-methylcholine chlo-
ride, MCh, Sigma-Aldrich) was administered through a catheter
with increased dosages of 0.025, 0.05, 0.1, and 0.2 mg/kg every
5 min. Mouse airway responsiveness was examined by expiratory
resistance (Re), inspiratory resistance (Ri) and dynamic lung
compliance (Cldyn). The relative area (R-area) was defined as the
area under the peak curve of Re or Ri and beyond the baseline
level during the 250 s time frame. The distance from the wave
trough to the baseline level of the Cldyn curve was adopted to
quantitatively assess lung compliance [25].
Counting of eosinophils and total cells in BALF
BALF was collected after airway hyperresponsiveness measure-
ments. After the final 0.2 mg/kg MCh challenges, the mice were
removed from the operation box. Using a 1 ml syringe, 0.5 ml
aliquots of 0.9% NaCl solution was injected into the trachea and
lungs through the tracheal cannula, the chests of mice were gently
massaged and rinsed for approximately 1 min, and then the liquid
was withdrawn with the same syringe. The process was repeated 3
times, and the total quantity of BALF was 1.2 ml–1.3 ml for each
sample. The cellular fraction from BALF was collected by
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resuspended in 1 ml saline. Total cell counts were obtained from
500 ml of the cell suspension using a blood cell analysis system
(Sysmex KX-21, Japan). Another 500 ml cell suspension was
prepared for eosinophil counts. Eosinophils were stained using
Eosin Y sodium solution (Amresco, high purity grade, USA), and
cell numbers were assessed using a hemocytometer (Sigma-
Aldrich, USA) and a microscope (Olympus). Neutrophils, macro-
phages or monocytes were not counted because of the limited
amount of BALF.
The relative number of eosinophils to total cell number in BALF
was used in this study as an indicator for eosinophil recruitment,
because it overcomes the inconsistency of BALF sample volume
between individual mice and is thus comparable within the study.
Relative number of eosinophils=eosinophil number in BALF/
total cell number in BALF.
Histological examination
Following BALF collection, the lungs were isolated for
histopathology slice preparation. All the samples were incubated
in fixation solution (saturated 2, 4, 6-trinitrophenol:formalin:gla-
cial acetic acid=15:5:1) for 24 hours at room temperature and
then cut into pieces, and stained with hematoxylin and eosin (H&E
Sigma-Aldrich, USA). The stained pieces were then embedded in
paraffin, sectioned into 10 mm slices and observed under a
microscope (Leica DM 4000B, Germany).
Detection of serum immunoglobulin E
For the second set of 64 balb/c mice blood was drawn after
finishing of the exposure and immunization treatments, and serum
samples were collected after centrifuging the blood (2400 rpm, i.e.
5006g, 4uC, 10 min) and stored at 280uC until analyzed. The
amounts of total IgE and anti-OVA-IgE in the serum from
different groups of mice were determined using the total IgE
ELISA kit (Biolegend, USA). The sensitivities are 15 pg/ml for
both ELISA kits of total IgE and anti-OVA-IgE. Since the anti-
OVA-IgE standards were not available, the levels of anti-OVA-
IgE could just be indicated as absorbance (492 nm) but not as
values of ng/ml.
Detection of the cytokines in lung tissue
After serum sample collection, the lungs were excised and
homogenized in 0.9% NaCl solution, and fractionation of the
soluble fraction was done by centrifugation (1500 rpm, i.e. 2006
g, 4uC, 10 min). The tissue levels of IL-4 and IFN-c were
measured by ELISA kits according to the manufacture’s instruc-
tions (eBioscience, USA). The sensitivities of all ELISA kits are
15 pg/ml.
Statistical analysis
Statistic Program for Social Sciences (SPSS, version 13.0) was
used for our data statistic analysis. Covariance analysis was
performed for the AHR assessment data, in which the biomarkers
(Ri, Re and Cldyn) were taken as dependent variables, DEHP
Figure 1. Exposure and immunization schedule.
doi:10.1371/journal.pone.0039008.g001
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taken as covariates, and F and p values were calculated. Data from
the other measurements were analyzed using the parametric tests
i.e. one-way ANOVA followed by the LSD test. P values less than
0.05 were considered statistically significant and all data were
expressed as means6standard deviation (SD) and exhibited in
graphs and charts. In figures 2, 3, 4, 5, the statistical test (LSD test
for figures 2, 3, 4, t test for figure 5) of two independent samples for
OVA only group were done only to OVA+DEHP30, OVA+-
DEHP300 and OVA+DEHP3000, but not to DEHP30,
DEHP300 and DEHP3000, in order to observe if any adjuvant
effect existed.
Results
Levels of serum IgE
Fig. 2a and b, shows the measurement data of serum total IgE
after DEHP-treatment in the absence or presence of OVA-
sensitization. Four important findings were revealed: (1) Exposure
for only DEHP (DEHP30, DEHP300, DEHP3000) did not cause
any changes in serum total IgE (T-IgE), and the T-IgE level for
these groups were not different from the saline control group; (2)
The serum total IgE levels of all OVA-immunized groups (OVA
only, OVA+DEHP30, OVA+DEHP300, OVA+DEHP3000) were
significantly inceased in relation to saline and DEHP only
exposure groups (saline control, DEHP30, DEHP300,
DEHP3000) (p,0.01); (3) From the scatter of Fig. 2b, a dose-
response relationship up to OVA+300 but not further between
logarithmic concentrations of OVA+DEHP and serum total IgE
levels was evident in Fig. 2b; (4) Most important, already the
lowest dose of OVA+DEHP30 caused a significant increase in
serum T-IgE compared with the OVA only group, which suggests
that an adjuvant effect occurs at low levels of DEHP.
From the results of analysis of anti-OVA-IgE in Fig. 2c, we saw
that: (1) anti-OVA-IgE (OVA-IgE) did differ between saline and
OVA control group; (2) the OVA-IgE levels in the highest DEHP
group (DEHP3000) and higher OVA+DEHP exposure groups
(OVA+DEHP300, OVA+DEHP3000) had significant differences
(p,0.05, p,0.05, p,0.01) compared with the saline group. (3) the
OVA-IgE levels in the all OVA+DEHP exposure groups
(OVA+DEHP30, OVA+DEHP300, OVA+DEHP3000) had no
statistic significant difference compared with the OVA exposure
alone group (p.0.05);
Cytokines in lung tissue
The levels of the Th1 cytokine IFN-c and the Th2 cytokine IL-4
were assessed in lung tissue samples (Fig. 3). OVA did not affect
the levels of IFN-c and only the highest dose of DEHP with or
without OVA increased IFN-c levels (Fig. 3a). This finding
suggests that Th1 cytokines were not induced in this exposure
model. In contrast, there were significant increases of IL-4 in the
OVA (p,0.05) and OVA+DEHP groups (p,0.01) compared with
saline control group (Fig. 3b). The lower doses of OVA+DEHP
(OVA+DEHP30 and OVA+DEHP300) did not significantly alter
IL-4 levels compared with OVA only group, while OVA+-
DEHP3000 did cause a significant potentiation (p,0.05). The IL-
4 response was even more stringent when IL-4 expression was
calculated and expressed related to IFN-c in the correspondning
sample.
The relative number of eosinophils to total cells in BALF
From figure 4 we can see, that the ratio of eosinophils to total
cells in BALF in the OVA-combined with DEHP exposure groups
(OVA only, OVA+DEHP30, OVA+DEHP300, OVA+-
Figure 2. Serum IgE. (a) Total IgE levels in the eight different
exposure groups. ** p,0.01, compared with the saline control; ##
p,0.01, compared with the OVA only group; (b) Dose-response
relationship between DEHP (+OVA) and total serum IgE levels; (c)
OVA-IgE levels in the eight different exposure groups. Group data were
expressed as means6standard deviation (SD). * p,0.05, ** p,0.01,
compared with the saline control.
doi:10.1371/journal.pone.0039008.g002
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group, p,0.05 and p,0.01). The DEHP only exposure groups
(DEHP30, DEHP300, DEHP3000) showed no significant effects
on the ratio of eosinophils to total cells (p.0.05), while the ratio in
OVA+DEHP3000 group was increased compared with OVA only
group (p,0.05), indicative of an adjuvant effect on eosinophil
recruitment.
Measurement of airway hyperresponsiveness (AHR)
Figure 5 shows the results of measurements of airway
responsiveness. (1) In all of the groups, the expiratory and
inspiratory resistance increased with the increase of methacholine
levels (p,0.01), while the Cldyn decreased (p,0.01). (2) In OVA-
sensitized mice (OVA only, OVA+DEHP30, OVA+DEHP300,
OVA+DEHP3000), the Ri and Re values were increased
compared with the same DEHP doses in saline-treated mice
(saline, DEHP30, DEHP300, DEHP300). (3) DEHP exposure had
no significant influence on the Ri, Re and Cldyn values (Ri,
F=0.609, p.0.05; Re, F=1.159, p.0.05; Cldyn, F=0.445,
p.0.05) compared with the saline control, but (4) OVA+DEHP
exposure resulted in a significantly enhanced expiratory resistance
and inspiratory resistance (Ri, F=12.804, p,0.01; Re,
F=11.329, p,0.01) compared with OVA only. In the OVA+-
DEHP3000 group (panel d, e, f.), there is a relatively high
resistance and relatively low compliance already at 0.025 mg/kg
MCh. This may be due to mucus (airway obstruction) in the
airways in addition to constriction of smooth muscles. (5) Further
multiple comparisons are summarized in table 1. According to the
data, DEHP at the highest exposure level promoted AHR in
OVA-sensitized mice, see Fig. 5 and Table 1.
Histological examination
Histological analyses of distal bronchial tissue revealed typical
pathological features of asthma-like inflammation and structural
alterations in the OVA-immunized groups (Fig. 6, panel E–H) In
contrast to the non-sensitized mice, OVA-sensitized animals
showed leukocyte infiltration in the surrounding peribronchiolar
areas, epithelial folding and thickened subepithelial cell layers
(airway remodeling), findings which are normally associated with
asthma in humans. There were two key findings as illustrated in
figure 6: (1) It was clear that moderate histological changes were
found in the OVA+DEHP30 group, whose DEHP exposure dose
was relatively low; (2) in the OVA+DEHP3000 group the
histopathologic changes were severe, with prominent airway
mucosa thickening and epithelial folding and a pronounced
airway obstruction, all signs of airway remodeling. Thus a dose-
dependent low dose sensitive effect of DEHP was identified on
airway tissue reactivity.
Result summary
The results of this study are summarized in Table 2.
In the result over-view and data summary presented in Table 2
we have divided the biomarkers (measured parameters) into three
groups. The first group is ‘‘non-sensitive biomarkers’’, include
serum OVA-IgE and INF-c. From a theoretical viewpoint the
serum OVA-IgE should be a sensitive biomarker, but this was not
confirmed in the present experimental set up. The second group is
‘‘moderately sensitive biomarkers’’, including IL-4, recruitment of
eosinophils and airway hyperresponsiveness (Re, Ri and Cldyn).
Our results shows that these biomarkers may indicate an adjuvant
effect, but only in the highest DEHP dose exposure group
(OVA+DEHP3000). The third group include total serum IgE and
histopathological examinations (airway remodeling and lung tissue
immune cell infiltration). These biomarkers were more affected by
Figure 3. IFN-c and IL-4 levels in lung tissue. (a) pulmonary tissue IFN-c levels in each group; (b) pulmonary tissue IL-4 levels in each group; (c)
IL-4/IFN-c ratios in each group. Group data were expressed as means6standard deviation (SD). * p,0.05, ** p,0.01, compared with the saline
control;
# p,0.05,
## p,0.01, compared with OVA only group.
doi:10.1371/journal.pone.0039008.g003
Figure 4. The relative number of eosinophil to total cell
numbers in BALF. Group data were expressed as means6standard
deviation (SD). * p,0.05 and ** p,0.01, compared with the saline
control;
# p,0.05, compared with the OVA only group.
doi:10.1371/journal.pone.0039008.g004
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DEHP in this model, and our result points to a dose-response
relationship.
Discussion
The main findings
The main findings of this study include: (1) Strong postive
associations exist between OVA-combined DEHP exposure and
serum total IgE, as well as histological examination. These positive
associations show dose-dependent low dose sensitive effects of
DEHP. (2) IL-4, eosinophil recruitment and AHR are also
effective indicators for DEHP at somewhat higher concentrations.
(3) Like other animal DEHP studies [17,18,22,24], we did not find
statistical association between OVA exposure and anti-OVA-IgE.
(4) Higher level DEHP exposure alone may cause significantly
increased IFN-c.
Adjuvant effect of DEHP
Our study suggests, that airway reactivity and immune
responses induced by DEHP-OVA co-exposure may be mediated
by an adjuvant effect of DEHP. In this study we find that, in the
absence of an allergen, OVA, DEHP exposure did not cause
obvious histological and physiological changes in the mice; while
with co-exposure with OVA, DEHP has the ability to stimulate the
body to produce large amounts of IgE, and to cause histological
changes such as cell infiltration in lung tissue and airway
remodeling at low exposure level; and to induce physiological
changes such as pulmonary dysfunction at higher exposure levels.
These phenomena can be explained by an adjuvant effect.
Adjuvant effect of DEHP involves two groups of important
mechanistic biomarkers: ‘‘immune response’’ and ‘‘asthma
pathology’’. The former include IgE, IgG1, IL-4, IFN-c, and the
latter include lung histopathology and function, eosinophil
recruitment. Some studies [17,20,22,23,24,26] had just focused
on DEHP-induced ‘‘immune response’’; one other study [21] had
just focused on DEHP-induced ‘‘asthma pathology’’. A literature
review has summarized these studies in detail, see table 2 in
Bornehag and Nanberg [13]. The present study is the first to our
knowledge that combines both groups of biomarkers for under-
standing the adjuvant effect of DEHP. In this study we have
assessed the changes of both two groups of biomarkers, and
defined a ‘‘DEHP-exposure mouse model’’, which is useful for
mechanistic research related to human allergic disorder.
So far the molecular mechanism of adjuvant effect of DEHP is
not clear. We have speculated that DEHP exposure may up-
regulate thymic stromal lymphopoitin (TSLP) protein expression
[27], and TSLP was found to up-regulate IgE expression and
Figure 5. Airway hyperresponsiveness (AHR) measurements in mice. Covariance analyses (SPSS) were used in these tests. (a) Ri values of
saline control and DEHP groups; (b) Re values of saline control and DEHP groups; (c) Cldyn values of saline control and DEHP groups; (d) Ri values of
OVA only and OVA+DEHP groups; (e) Re values of OVA only and OVA+DEHP groups; (f) Cldyn values of OVA only and OVA+DEHP groups. Group data
were expressed as means6standard deviation (SD).
doi:10.1371/journal.pone.0039008.g005
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for understanding the molecular mechanism on the adjuvant effect
of DEHP, in order to effectively prevent related health problems in
the future.
‘‘Conditional risk factor’’ and ‘‘conditional attenuating
agent’’
The unbalance of Th1 and Th2 immune response is an
important pathological basis for allergy and allergic asthma. IFNc
is a key biomarker for Th1, and IgE and IL-4 are key biomarkers
for Th2 immune response. In this study we found DEHP exposure
alone (Fig. 3a, group DEHP3000) caused an limited but significant
(p,0.05) increase in IFN-c. Our study results suggest that, the
biological effects of DEHP are different depending on presence or
absence of an antigen (OVA). With OVA co-exposure, DEHP is a
strong agent to promote Th2-related immune responses, (allergy
and asthma); but without OVA co-exposure, DEHP becomes a
weak agent for a Th1 immuno response. This situation is similar to
what we found in the adjuvant effect of formaldehyde [30], (see the
Fig. 6). Therefor DEHP is a potential ‘‘conditional risk factor’’.
It is also interesting that DEHP is not only a ‘‘conditional risk
factor’’, but also a ‘‘conditional attenuating agent’’. In a specially
designed long-term low-dose OVA co-exposure model, DEHP was
shown to induce OVA-desensitization. In mice [31] find that:
compared with the OVA-sensitised control mice, multiple co-
exposures to DEHP+OVA reduced the OVA-IgG1 level and
reduced the OVA-IgE/OVA-IgG2a ratio. This suggests that
DEHP may attenuate long-term allergic sensitisation, as the IgE/
IgG2a ratio has been shown to correlate with the degree of
anaphylaxis. So, like allergens, DEHP is also of two-direction
immune effect to induce sensitization and desensitization, but the
molecular mechanisms of DEHP causing two-direction effect is
certainly different.
Serum OVA-IgE and serum T-IgE
As expected, a statistical difference of OVA-IgE was fund
between saline and OVA control group (p,0.05) and an adjuvant
effect was also fund in DEHP 3000 group compared with the
saline control (p,0.05). In contrast it was unexpected that the
levels of OVA-IgE in the OVA+DEHP exposure groups
(OVA+DEHP30, OVA+DEHP300, OVA+DEHP3000) showed
no statistically significant difference compared with the OVA
exposure alone group (p.0.05). Although our results are in
agreement with other related in vivo animal studies on adjuvant
effect of DEHP [17,20,22,24,31], it seems contrary to an adjuvant
effect of DEHP. One possible reason is that, as we know, the
amount of IgE in the body is low, and in relation to T-IgE the
fraction of specific OVA-IgE is even lesser, and a substantial
amount exist bound on cell membranes of mast cells and basophils
in the tissue. Therefor the OVA-IgE level remaining in circulating
blood may be near to the limit to be detected by the ELISA kit. A
clear circumstantial evidence for the above assumption is that the
standard deviations of OVA-IgE measurements were relatively
large, this phenomenon often results from poor measuring method
but not from the real level of biomarker, and the inaccuracy of
measuring method makes the statistic analysis with no significant
difference hard to interpret.
It is very difficult to find studies from literature that has analysed
serum T-IgE for characterizing an adjuvant effect of DEHP, the
only one we found was carried out by Lee and his colleagues [26].
Their results (Fig. 5a of their paper) and our studies (Fig. 2a and
Fig. 2b) are consistent: the serum T-IgE levels in antigen + DEHP
exposure groups were significantly higher than that in antigen
exposure alone group, and showing a dose-dependent pattern.
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PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e39008The main difference between the two studies was that the antigen
we used was OVA, while the antigen Lee used was keyhole limpet
hemocyanin (KLH). The results of two studies suggest that serum
T-IgE is an effective and sensitive biomarker reflecting adjuvant
effects of DEHP. Moreover, according to the consistency of dose-
response between serum T-IgE and lung histopathology, it is
suggested that the increased T-IgE level may be an important
pathological molecular event for DEHP-induced pulmonary
inflammation of allergic asthma.
The identified low-dose effect
Unfortunately, neither Lee’s study nor our study had found the
threshold (maximum non-effect dosage) for the serum T-IgE
induced by DEHP in antigen co-exposure. Because in the two
studies, even in the lowest exposure groups designed, 30 mg/kg
bw/day (cumulative dose 1.53 mg DEHP/kg/51 d) in ours and
2 mg/kg bw/2 d (cumulative dose 14 mg DEHP/kg/21 d) in Lee
(2004) the serum T-IgE still increased significantly, so more studies
are needed. But the here presented data based on our
experimental results, indicate that the lowest dose, 1.53 mg
DEHP/kg/51 d, i.e 0.03 mg DEHP/kg/d, during prolonged
exposure may have severe modulating effects on the immune
system and thus be well above a risk level of exposure, which may
be used for scientific reference.
Figure 6. Histopathology of lung tissue with parenchymal inflammation (tissue cell infiltration) and airway remodeling. Lung tissue
was fixed, stained with H&E, and sectioned in 10-mm slices. R: Bronchial remodeling; ----c: lung tissue cell infiltration; N: normal conditions; S: slight
changes; M: moderate changes; V: severe changes. AM ––c: airway mucus. (A. saline control; B. DEHP30; C. DEHP300; D. DEHP3000; E. OVA only; F.
OVA+DEHP30; G. OVA+DEHP300; H. OVA+DEHP3000).
doi:10.1371/journal.pone.0039008.g006
Table 2. Summary of the experimental results.
Parameters System for evaluating
asthma DEHP exposure groups OVA-combined DEHP exposure groups
Saline
control DEHP30 DEHP300 DEHP3000
OVA
only
OVA+ DEHP
30
OVA+ DEHP
300
OVA+ DEHP
3000
Serum OVA-IgE – NS NS q* – ns ns ns
Th1 cytokine: IFN-c –N S N S q* – ns ns ns
Th2 cytokine: IL-4 – NS NS NS – ns ns q
#
IL-4/IFN-c ratios – NS NS NS – ns ns q
##
Eosinophil/Total Cells – NS NS NS – ns ns q
#
AHR: Re – NS NS NS – ns ns q
##
AHR: Ri – NS NS NS – ns ns q
#
AHR: Cldyn – NS NS NS – ns ns q
##
Serum total IgE – NS NS NS – q
## q
## q
##
Histopathology: Tissue cell infiltration Normal Normal Slight Slight Normal Moderate Moderate Severe
Histopathology: Airway remodeling Normal Normal Slight Slight Slight Moderate Moderate Severe
–: As statistical control group; Compared with saline control: NS p.0.05,
*p,0.05,
**p,0.01; Compared with OVA only group: ns p.0.05,
#p,0.05,
##p,0.01.
doi:10.1371/journal.pone.0039008.t002
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